

Margetuximab SOPHIA

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE



ADJUSTMENTS

Quality of life



Serious and disabling adverse effects




Other adjustments



Margetuximab SOPHIA

SCORE

CURATIVE




Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE



Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Therapeutic Indication: Treatment of adult patients who have received two or more prior anti-HER2 regimes, at least one of which was for metastatic disease
Experimental Arm: Margetuximab + ChT
Control Arm: Trastuzumab plus ChT

